+1 Recommend
1 collections
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Comparison of Efficacy and Tolerability between Two Gel-Forming Timolol Maleate Ophthalmic Solutions in Patients with Glaucoma or Ocular Hypertension


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Purpose: To compare two gel-forming timolol maleate ophthalmic solutions, Timoptol XE<sup>®</sup> and Lizmon TG<sup>®</sup>, in regard to efficacy and tolerability in patients with glaucoma or ocular hypertension by means of a patient-masked prospective randomized crossover study. Subjects and Methods: A total of 37 patients with glaucoma or ocular hypertension under treatment with antiglaucoma ophthalmic solutions including 0.5% twice-daily timolol maleate participated in this study. Only timolol maleate was withdrawn and either Timoptol XE or Lizmon TG was randomly allocated. After instillation for 1 month, the other ophthalmic solution was subsequently instilled for another month. Routine ophthalmic examination including slit-lamp examination and intraocular pressure (IOP) monitoring was conducted before instillation of gel-forming ophthalmic solutions and just after completing the instillation of each ophthalmic solution. Patient questionnaire surveys were also performed just after completing the instillation of each ophthalmic solution. Results: Mean IOP, just before the withdrawal of timolol ophthalmic solution, was 16.4 ± 2.9 mm Hg. At the end of Timoptol XE or Lizmon TG instillation, mean IOPs were 16.3 ± 2.5 or 16.3 ± 3.0 mm Hg, respectively. The results of the questionnaire survey showed no significant difference between Timoptol XE and Lizmon TG in regard to all survey items. Twenty-nine patients (78.4%) preferred to use gel-forming timolol solutions rather than twice-daily timolol ophthalmic solution. The presence of concurrently used ophthalmic solutions did not effect the incidences of subjective symptoms. The incidences of objective adverse effects were not significantly different between two gel-forming timolol ophthalmic solutions. Conclusion: Both gel-forming timolol ophthalmic solutions could be good choices for glaucoma treatment.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: not found
          • Article: not found

          Gelrite®: A novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol

            • Record: found
            • Abstract: found
            • Article: found

            Comparison of the Effects of Preserved and Unpreserved Formulations of Timolol on the Ocular Surface of Albino Rabbits

            Thirty-six albino rabbits, randomly divided into six groups, were used to study their ocular tolerance to (a) 0.25 and 0.50% Timoptol ® preserved with 0.01% benzalkonium chloride, (b) 0.25 and 0.50% Timoptol-LP ® , a gel-forming solution preserved with 0.012% benzododecinium bromide, and (c) 0.25 and 0.50% Timabak ® unpreserved in the ABAK ® eyedrops dispenser. All eyedrops were applied in the right eye for 60 days. A clinical follow-up with slitlamp examination and break-up time evaluation was performed for 2 months. At the end of the experimentation, the animals were sacrificed and their eyes enucleated for histological analyses of the conjunctiva and cornea. There was no significant difference in the clinical examination between each group, except for the break-up time evaluation between Timoptol and Timabak at each concentration which was better with the unpreserved timolol. Histological results showed a significant difference in the corneal stroma edema between preserved and unpreserved timolol. This study confirms that using unpreserved timolol may be beneficial for the long-term treatment of glaucomatous patients as it increases tear film stability and decreases epithelial permeability and stromal aggression of the cornea.
              • Record: found
              • Abstract: not found
              • Article: not found

              Clinical evaluation of a new formula of timolol maleate (WP-934 ophthalmic solution)


                Author and article information

                S. Karger AG
                February 2003
                06 February 2003
                : 217
                : 1
                : 31-38
                aIchikawadaimon Municipal Hospital, Ichikawadaimon, and bDepartment of Ophthalmology, University of Yamanashi, Faculty of Medicine, Tamaho, Japan
                68248 Ophthalmologica 2003;217:31–38
                © 2003 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                : 26 April 2002
                Page count
                Figures: 3, Tables: 2, References: 22, Pages: 8
                Original Paper

                Vision sciences,Ophthalmology & Optometry,Pathology
                Timolol maleate,Reversible thermosetting gel,Tolerability,Intraocular pressure,Gel-forming ophthalmic solution,Ion-activated gel


                Comment on this article